New theranostic approaches in inflammatory diseases using [89ZR]ZR-ANTI-TNF-α PET imaging

Abstract

Immune-mediated inflammatory diseases are chronic disorders involving abnormal activation of the immune system, leading to persistent inflammation and tissue damage. They share mechanisms such as overexpression of pro-inflammatory cytokines. Anti-TNF-a agents like adalimumab are effective, but up to 40% of patients do not respond. This thesis developed a PET-based methodology using [89Zr]Zr-DFOadalimumab to analyze biodistribution and pharmacokinetics in murine models of inflammatory bowel disease, uveitis, and rheumatoid arthritis, administered intravenously, subcutaneously, and intravitreally. This work opens new possibilities for both diagnosis and individualized therapeutic monitoring in inflammatory diseases (theragnosis).